DP-DCT 1.0:A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform
A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.
Also called NCT07595289
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose other
- Phase
- Not applicable
- Enrolled
- 120 participants
- Registry
-
NCT07595289
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07595289. Randomized; no masking; primary purpose other. Start 2026-08-01 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- DP-DCT 1.0:A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform
- Acronym
- DP DCT
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- Dapagliflozin (10mg Tab)
- Intervention (Device)
- Continuous Glucose Monitoring (CGM)
- Intervention (Other)
- Self-Monitoring of Blood Glucose (SMBG)
- Lead sponsor
- The Third Xiangya Hospital of Central South University
Record details
- Record id
cardio:ct-nct07595289- Content hash
efa4135e0163cef76b1943f8af9b7e3df66dd56ecd5d6d39d818c26779ea39d0